Table 3. Genetic and epigenetic alterations in circulating tumour cells in pancreatic ductal adenocarcinoma and biliary tract cancer, 2013–2017.
| Author (year) | Target | Biliary
tract cancer, number |
Pancreatic ductal
adenocarcinoma, number |
Benign
lesions, number |
Healthy
volunteers, number |
Detected | Sensitivity | Specificity | Area
under the curve |
|---|---|---|---|---|---|---|---|---|---|
| Ankeny et al. (2016) 120 | K-ras | - | 72 | 28 | - | - | 75% | 96.4% | 0.867 |
| Kulemann et al. (2016) 121 | K-ras | - | 21 | - | 10 | 80% (stage IIA/IIB)
91% (stage III/IV) |
- | - | - |
| Singh et al. (2015) 122 | ctDNA,
K-ras |
- | - | - | - | - | 65.3% | 61.5% | 0.6681 |
| Kinugasa et al. (2015) 123 | K-ras | - | 141 | 20 | 20 | - | 62.6% | - | - |
| Takai et al. (2015) 124 | K-ras | - | 259 | - | - | - | 29.2% | - | - |
| Sausen et al. (2015) 125 | ctDNA | - | 77 | - | - | - | 43% | - | - |
| Kulemann et al. (2015) 126 | CTC
K-ras |
- | 11 | - | 9 | 75% (stage IIb)
71% (stage III) |
- | - | - |
| Zhang et al. (2015) 127 | DAPI
+, CD45-,
CK +, CEP8 > 2 + |
- | 22
Validation cohort: 11 |
6
8 |
30
10 |
68.2% |
63.6% |
94.4% |
0.84 |
| Wu et al. (2014) 128 | K-ras | - | 36 | - | 25 | - | 0 | 0 | - |
| Bidard et al. (2013) 129 | CK,
CD45 |
- | 79 | - | - | 11% | - | - | - |
| Bobek et al. (2014) 130 | DAPI,
CK, CEA, Vimentin |
- | 24 | - | - | 66.7% | - | - | - |
| Rhim et al. (2014) 131 | DAPI, CD45,
CK, PDX-1 |
- | 11 | 21 | 19 | 78% | - | - | - |
| Iwanicki-Caron et al. (2013) 132 | CTC | - | 40 | - | - | - | 55.5% | 100% | - |
| Sheng et al. (2014) 133 | CTC | - | 18 | - | - | 94.4% | - | - | - |
| Catebacci et al. (2015) 134 | CTC (in portal venous
blood at EUS) |
2 | 14 | - | - | 100% (pulmonary vein blood)
22.2% (peripheral blood) |
- | - | - |
| Earl et al. (2015) 135 | CTC | - | 35 | - | - | 20% | - | - | - |
| Cauley et al. (2015) 136 | Circulating epithelial
cells |
- | 105 | 34 | 9 | 49% | - | - | - |
| Kamande et al. (2013) 137 | DAPI, CD45,
CK |
- | 12 | - | - | 100% | - | - | - |